2. Search Result
Search Result
Results for "

loss-of-function

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149555
    DNL343

    		Eukaryotic Initiation Factor (eIF) Neurological Disease
    DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .
    DNL343
  • HY-100886
    BAY1082439

    		PI3K Apoptosis Cancer
    BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
    BAY1082439
  • HY-164221A
    Rapirosiran sodium

    ALN-HSD sodium

    		 17β-HSD Metabolic Disease
    Rapirosiran sodium is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran sodium can be used for the study of Non-alcoholic steatohepatitis.
    Rapirosiran sodium
  • HY-164221
    Rapirosiran

    ALN-HSD; ALN-288996; AD-288996

    		 17β-HSD Metabolic Disease
    Rapirosiran is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran can be used for the study of Non-alcoholic steatohepatitis.
    Rapirosiran
  • HY-143615
    RET-IN-10

    		RET Cancer
    RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18) .
    RET-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: